ProteaPex Therapeutics is working on research and development of the Extracellular Matrix Protection Factors (ECPFs). The ECPFs are a platform technology that can be tailored to several members of the Matrix Metalloprotease (MMP) family. The patented technology boasts development of potential therapeutics for indications in disease in which extracellular matrix degradation is hallmark such as periodontal disease (ECPF-2), osteoarthritis (ECPF-1), lung fibrosis (ECPF-3), cancer metastasis, wound healing and fracture non-union.